IMI name change
This article was originally published in The Tan Sheet
IMI International Medical Innovations will change its name to PreMD Inc. effective in September, the Toronto-based firm announces May 25. The new name "describes the role the company's products fill: predicting disease at an early stage in order to prevent its progression, or from occurring at all." IMI's PREVU-branded skin sterol tests are marketed and distributed by McNeil Consumer Healthcare (1"The Tan Sheet" June 7, 2004, p. 10)...
You may also be interested in...
McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.